ESMO 2025: Padcev plus Keytruda promising in first-line advanced HNSCC

"ESMO 2025: Padcev plus Keytruda promising in first-line advanced HNSCC" was originally created and published by Clinical ...
CURE

Cancer Vaccine Plus Keytruda Slow Advanced Melanoma Progression

IO102-IO103 plus Keytruda improved median PFS by 8.4 months over Keytruda alone in advanced melanoma patients. The ...

Merck Keytruda formulations undergo FDA priority review for bladder cancer

Merck (NYSE:MRK) announced on Thursday that the FDA has granted priority review for two of its marketing applications aimed at expanding the U.S. indications of injectable and intravenous versions of ...

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients …

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...
CURE

FDA Accepts Application for Padcev Plus Keytruda For Some With Bladder Cancer

The FDA accepted an application for Padcev plus Keytruda for patients with muscle-invasive bladder cancer ineligible for ...
Benzinga.com

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...

2 Beaten-Down Stocks to Buy and Hold for the Next Decade

The pharmaceutical company has also earned approval for Wegovy in treating metabolic dysfunction-associated steatohepatitis ...
WPRI 12

Data presented at AACR IO meeting in Los Angeles

CAMBRIDGE, United Kingdom, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic ...